JP7357613B2 - リンパ球の拡大方法 - Google Patents
リンパ球の拡大方法 Download PDFInfo
- Publication number
- JP7357613B2 JP7357613B2 JP2020524540A JP2020524540A JP7357613B2 JP 7357613 B2 JP7357613 B2 JP 7357613B2 JP 2020524540 A JP2020524540 A JP 2020524540A JP 2020524540 A JP2020524540 A JP 2020524540A JP 7357613 B2 JP7357613 B2 JP 7357613B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- expansion
- certain embodiments
- lymphocytes
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1107—B cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582163P | 2017-11-06 | 2017-11-06 | |
| US62/582,163 | 2017-11-06 | ||
| PCT/EP2018/080343 WO2019086711A1 (en) | 2017-11-06 | 2018-11-06 | Method for expansion of lymphocytes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501596A JP2021501596A (ja) | 2021-01-21 |
| JP2021501596A5 JP2021501596A5 (cg-RX-API-DMAC7.html) | 2021-10-28 |
| JP7357613B2 true JP7357613B2 (ja) | 2023-10-06 |
Family
ID=64332272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524540A Active JP7357613B2 (ja) | 2017-11-06 | 2018-11-06 | リンパ球の拡大方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200338125A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3707245A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7357613B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111801415A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018361561C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3081479A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019086711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3877055A1 (en) | 2018-11-05 | 2021-09-15 | Ludwig Institute for Cancer Research Ltd | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
| CA3118027A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof |
| CA3145196A1 (en) * | 2019-06-24 | 2020-12-30 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的t細胞の製造方法 |
| CA3161510A1 (en) * | 2019-12-18 | 2021-06-24 | CBio A/S | Improved process for culturing tumor-infiltrating lymphocytes for therapeutic use |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| KR20230019460A (ko) * | 2020-05-29 | 2023-02-08 | 상하이 준셀 테라퓨틱스 컴퍼니 리미티드 | 종양 침윤 림프구의 종자세포 배지 및 이의 용도 |
| AU2021320556A1 (en) | 2020-08-07 | 2023-03-09 | Neogene Therapeutics B.V. | Methods to enrich genetically engineered T cells |
| CA3192356A1 (en) * | 2020-08-17 | 2022-02-24 | Northwestern University | B-cell based immunotherapy for the treatment of glioblastoma and other cancers |
| TWI895549B (zh) | 2020-11-19 | 2025-09-01 | 大陸商蘇州沙礫生物科技有限公司 | 腫瘤浸潤淋巴細胞的培養方法及其用途 |
| CN112501308B (zh) * | 2020-11-30 | 2025-10-10 | 中国水产科学研究院珠江水产研究所 | 一组鳖科动物线粒体全基因组扩增通用引物 |
| US20240043801A1 (en) * | 2020-12-24 | 2024-02-08 | Suzhou Grit Biotechnology Co., Ltd. | Preparation method for tumor infiltrating lymphocyte and use thereof |
| CN114686430A (zh) * | 2020-12-31 | 2022-07-01 | 上海赛比曼生物科技有限公司 | 一种制备til的方法 |
| AU2022210312A1 (en) * | 2021-01-20 | 2023-08-31 | Neogene Therapeutics B.V. | Engineered antigen presenting cells |
| CN115315509B (zh) * | 2021-02-08 | 2024-05-07 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的制备方法及其用途 |
| BR112023022485A2 (pt) * | 2021-04-30 | 2024-01-09 | Centre Hospitalier Univ Vaudois Chuv | Expansão de linfócitos em um único recipiente |
| US20240207319A1 (en) | 2021-05-06 | 2024-06-27 | Ludwig Institute For Cancer Research Ltd | Compositions and methods for immunotherapy |
| KR20240023426A (ko) * | 2021-06-22 | 2024-02-21 | 아킬레스 테라퓨틱스 유케이 리미티드 | 항원-특이적 t 세포를 생산하는 방법 |
| US20240360410A1 (en) * | 2021-08-03 | 2024-10-31 | Suzhou Grit Biotechnology Co., Ltd. | Modified tumor infiltrating lymphocyte and use thereof |
| WO2023049733A2 (en) * | 2021-09-21 | 2023-03-30 | The University Of Chicago | Methods and composition using patient-derived autologous neoantigens for treating cancer |
| CN115433713B (zh) * | 2022-03-03 | 2023-10-27 | 中山大学孙逸仙纪念医院深汕中心医院 | 一种自体肿瘤引流淋巴结淋巴细胞的制备方法及其应用 |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
| WO2025081198A1 (en) * | 2023-10-13 | 2025-04-17 | Northwestern University | B cell production and expansion |
| WO2025131119A1 (en) * | 2023-12-22 | 2025-06-26 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
| EP4752217A1 (en) | 2024-11-28 | 2026-06-03 | invIOs GmbH | Manufacturing method for activated lymphocytes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525754A (ja) | 2014-06-11 | 2017-09-07 | ポリバイオセプト アーベー | 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP1995316A1 (de) | 2007-05-25 | 2008-11-26 | Qiagen GmbH | Verfahren zur schonenden Zellaufreinigung, Zellgewinnung und Transfektion von Zellen |
| EP2009095A1 (en) | 2007-06-28 | 2008-12-31 | Innovalor AG | Method of generating glucose-responsive cells |
| US8629098B2 (en) | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
| CN101824400B (zh) * | 2009-03-05 | 2012-08-08 | 中国科学院微生物研究所 | 一种放大增殖抗原特异性t细胞的方法 |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US9115402B2 (en) * | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| US10023657B2 (en) | 2010-10-01 | 2018-07-17 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| BR112014014591A8 (pt) * | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| SG11201702191YA (en) * | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| CN107075479A (zh) * | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| WO2017192924A1 (en) * | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
-
2018
- 2018-11-06 CA CA3081479A patent/CA3081479A1/en active Pending
- 2018-11-06 CN CN201880079423.3A patent/CN111801415A/zh active Pending
- 2018-11-06 WO PCT/EP2018/080343 patent/WO2019086711A1/en not_active Ceased
- 2018-11-06 US US16/761,711 patent/US20200338125A1/en active Pending
- 2018-11-06 EP EP18804249.3A patent/EP3707245A1/en active Pending
- 2018-11-06 JP JP2020524540A patent/JP7357613B2/ja active Active
- 2018-11-06 AU AU2018361561A patent/AU2018361561C1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525754A (ja) | 2014-06-11 | 2017-09-07 | ポリバイオセプト アーベー | 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖 |
Non-Patent Citations (3)
| Title |
|---|
| Ann Transl Med,2016年,Vol. 4, No. 14, 262,P. 1-9 |
| Immunology,2008年,Vol. 125,P. 229-240 |
| Oncotarget,2016年,Vol. 7, No. 29,P. 46173-46186 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200338125A1 (en) | 2020-10-29 |
| EP3707245A1 (en) | 2020-09-16 |
| AU2018361561B2 (en) | 2025-01-30 |
| CN111801415A (zh) | 2020-10-20 |
| CA3081479A1 (en) | 2019-05-09 |
| AU2018361561A1 (en) | 2020-05-07 |
| WO2019086711A1 (en) | 2019-05-09 |
| AU2018361561C1 (en) | 2025-07-03 |
| JP2021501596A (ja) | 2021-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018361561B2 (en) | Method for expansion of lymphocytes | |
| AU2022201222B2 (en) | Delivery of biomolecules to immune cells | |
| US20210382068A1 (en) | Hla single allele lines | |
| US20210104294A1 (en) | Method for predicting hla-binding peptides using protein structural features | |
| TW202021982A (zh) | T細胞受體構築體及其用途 | |
| US20180161366A1 (en) | Methods of obtaining mononuclear blood cells and uses thereof | |
| US20190160098A1 (en) | Chimeric antigen receptors and methods of use thereof | |
| US20240327491A1 (en) | T cell receptors specific for tumor-associated antigens and methods of use thereof | |
| WO2023070080A1 (en) | Knockout of regnase-1 and or roquin-1 to enhance car-t cell activity | |
| US20230048361A1 (en) | Methods of culturing t cells and uses of same | |
| AU2021375493A1 (en) | Use of tumor-independent antigens in immunotherapies | |
| JP2025519477A (ja) | T細胞活性を調節するための多重特異性分子及びその使用 | |
| HK40030363A (en) | Method for expansion of lymphocytes | |
| KR20240075776A (ko) | 유도 만능 줄기 세포-기반 암 백신 | |
| CN117693357A (zh) | 基于诱导多能干细胞的癌症疫苗 | |
| CN117460742A (zh) | 用于增强的干细胞样记忆t细胞工程化的材料和方法 | |
| US20240325535A1 (en) | Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout | |
| CN120693174A (zh) | T细胞受体构建体及其用途 | |
| Kandage | Modulating anti-tumour-specific CD8+ cytotoxic T lymphocyte responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210917 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210917 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220830 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220909 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230904 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230926 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7357613 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |